A study to learn how safe the study treatment actinium-225-macropa-pelgifatamab (BAY3546828) is, how it affects the body, how it moves into, through and out of the body, and about its anticancer activity in men with advanced metastatic castration-resistant prostate cancer (mCRPC)

2022-502623-22-00 Protocol 22143 Human pharmacology (Phase I) - First administration to humans Authorised, recruiting

Start 18 Sep 2023 · Status Authorised, recruiting · 4 EU/EEA countries · 13 sites · Protocol 22143

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruiting
Participants planned 232
Countries 4
Sites 13

Metastatic castration-resistant prostate cancer

Key facts

Sponsor
Bayer AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
18 Sep 2023 → ongoing
Decision date (initial)
2023-07-12
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2022-502623-22-00
ClinicalTrials.gov
NCT06052306

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metastatic castration-resistant prostate cancer

VersionLevelCodeTermSystem organ class
21.1 PT 10036909 Prostate cancer metastatic 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Bayer AG

Sponsor organisation
Bayer AG
City
Leverkusen
Postcode
51368
Country
Germany

Scientific contact point

Organisation
Bayer AG
Contact name
Therapeutic Area Head

Public contact point

Organisation
Bayer AG
Contact name
Therapeutic Area Head

Locations

4 EU/EEA countries · 13 investigational sites

By country

CountryMS statusPlanned subjectsSites
Finland Ongoing, recruitment ended 45 5
Italy Authorised, recruitment pending 8 2
Netherlands Ongoing, recruitment ended 25 2
Sweden Authorised, recruitment pending 12 4
Rest of world
Switzerland, Canada, United Kingdom, United States
142

Investigational sites

Finland

5 sites · Ongoing, recruitment ended
HUS-yhtymae
Clinical Trial Unit, Comprehensive cancer centre, Haartmaninkatu 4, 00290, Helsinki
Tampere University Hospital
Department of Oncology, Elamanaukio 2, 33520, Tampere
Pohjois-Savon hyvinvointialue
Department of Oncology, Puijonlaaksontie 2, P. O. Box 1711, Kuopio
Clinical Research Services Turku CRST Oy
Department of Oncology and Radiotherapy Turku University Hospital, Joukahaisenkatu 2 B, 20520, Turku
Mehilaeinen Oy
Docrates Mehiläinen Cancer Center, Saukonpaadenranta 2, 00180, Helsinki

Italy

2 sites · Authorised, recruitment pending
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Nuclear Medicine, Via Mariano Semmola 52, 80131, Naples
Istituto Europeo Di Oncologia S.r.l.
Nuclear Medicine, Via Giuseppe Ripamonti 435, 20141, Milan

Netherlands

2 sites · Ongoing, recruitment ended
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Medical Oncology, Dr. Molewaterplein 40, 3015 GD, Rotterdam
Universitair Medisch Centrum Groningen
Medical Oncology, Hanzeplein 1, 9713 GZ, Groningen

Sweden

4 sites · Authorised, recruitment pending
Sahlgrenska University Hospital-Vaestra Goetalandsregionen
Verksamhet onkologi, Bla Straket 5, 413 46 Goteborg, Bla Straket 5, Goteborgs Annedal, Goteborg
Uppsala University Hospital
KFUE, Blod och tumörsjukdomar, Akademiska Sjukhuset, Uppsala, Akademiska Sjukhuset, 751 85, Uppsala
Karolinska University Hospital
Fas 1-enheten Solna, CKC, Tema Cancer, Eugeniavagen 3, 171 64, Solna
Region Skane Skanes Universitetssjukhus
KFE Hematologi, onkologi och strålningsfysik, Lasarettsgatan 23, 221 85 Lund, Entregatan 7, 222 42, Lund

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Finland 2023-09-18 2023-09-20 2025-11-19
Netherlands 2024-06-13 2024-08-16 2025-11-19

Application history

26 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-04-13 Finland Acceptable
2023-07-03
2023-07-12
2 NON SUBSTANTIAL MODIFICATION NSM-1 2023-07-13 Finland Acceptable
2023-07-03
2023-07-13
3 NON SUBSTANTIAL MODIFICATION NSM-2 2023-07-14 Finland Acceptable
2023-07-03
2023-07-14
4 SUBSTANTIAL MODIFICATION SM-1 2023-07-14 Finland Acceptable
2023-08-21
2023-08-21
5 SUBSEQUENT ADDITION OF MSC APP-5 2023-08-24 Acceptable
2023-08-21
2023-11-10
6 SUBSTANTIAL MODIFICATION SM-2 2023-10-04 Finland Acceptable 2023-11-06
7 SUBSTANTIAL MODIFICATION SM-3 2023-11-22 Finland Acceptable
2024-01-11
2024-01-12
8 SUBSTANTIAL MODIFICATION SM-4 2024-05-06 Acceptable 2024-05-24
9 SUBSTANTIAL MODIFICATION SM-5 2024-06-20 Finland Acceptable
2024-08-05
2024-08-08
10 NON SUBSTANTIAL MODIFICATION NSM-3 2024-10-09 Finland Acceptable
2024-08-05
2024-10-09
11 SUBSTANTIAL MODIFICATION SM-6 2024-11-14 Finland Acceptable
2024-12-30
2025-01-03
12 NON SUBSTANTIAL MODIFICATION NSM-4 2025-02-06 Finland Acceptable
2024-12-30
2025-02-06
13 SUBSTANTIAL MODIFICATION SM-7 2025-02-27 Finland Acceptable 2025-04-14
14 SUBSEQUENT ADDITION OF MSC APP-14 2025-02-28 Acceptable
2024-12-30
2025-05-14
15 SUBSEQUENT ADDITION OF MSC APP-15 2025-03-04 Acceptable
2024-12-30
2025-05-27
16 NON SUBSTANTIAL MODIFICATION NSM-5 2025-06-05 Finland Acceptable
2024-12-30
2025-06-05
17 SUBSTANTIAL MODIFICATION SM-8 2025-06-11 Finland Acceptable
2025-09-10
2025-09-10
18 NON SUBSTANTIAL MODIFICATION NSM-6 2025-09-11 Finland Acceptable
2025-09-10
2025-09-11
19 NON SUBSTANTIAL MODIFICATION NSM-7 2025-09-11 Finland Acceptable
2025-09-10
2025-09-11
20 SUBSTANTIAL MODIFICATION SM-9 2025-09-18 Finland Acceptable 2025-10-30
21 SUBSTANTIAL MODIFICATION SM-10 2025-10-31 Finland Acceptable
2026-01-19
2026-01-20
22 NON SUBSTANTIAL MODIFICATION NSM-8 2026-03-27 Finland Acceptable
2026-01-19
2026-03-27
23 SUBSTANTIAL MODIFICATION SM-11 2026-04-01
24 SUBSTANTIAL MODIFICATION SM-12 2026-04-21 Finland Acceptable 2026-05-25
25 SUBSTANTIAL MODIFICATION SM-13 2026-04-21 Acceptable 2026-05-12
26 NON SUBSTANTIAL MODIFICATION NSM-9 2026-05-29 Finland Acceptable
2026-01-19
2026-05-29